Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging

Nuclear Medicine and Biology

Volumn 36, Issue 4, 2009, Pages 455-465

  Evens, Nele ^a   Muccioli, Giulio G ^b   Houbrechts, Nele ^a   Lambert, Didier M ^b   Verbruggen, Alfons M ^a   Van Laere, Koen ^a   Bormans, Guy M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

2 oxoquinolines; CB2 receptor; PET

Indexed keywords

1 (2,4 DICHLOROPHENYL) 6 FLUORO N PIPERIDIN 1 YL 1,4 DIHYDROINDENO[1,2 C]PYRAZOLE 3 CARBOXAMIDE; 2 AMINO 3 BUTYLOXY 4 METHOXYBENZALDEHYDE; 2 NITRO 3 BUTYLOXY 4 METHOXYBENZALDEHYDE; 2 NITRO 3 HYDROXY 4 METHOXYBENZALDEHYDE; 2 OXO 7 FLUOROETHOXY 8 BUTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID CYCLOHEXYLAMIDE; 2 OXO 7 HYDROXY 8 BUTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID CYCLOHEXYLAMIDE; 2 OXO 7 METHOXY 8 BUTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 2 OXO 7 METHOXY 8 BUTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID CYCLOHEXYLAMIDE; 2 OXO 7 METHOXY 8 BUTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID METHYL ESTER; CANNABINOID 2 RECEPTOR; CARBON 11; FLUORINE 18; QUINOLINE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SPLEEN;

ANIMALS; AUTORADIOGRAPHY; CARBON RADIOISOTOPES; FLUORINE RADIOISOTOPES; HUMANS; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; QUINOLONES; RECEPTOR, CANNABINOID, CB2; SPLEEN; STAINING AND LABELING; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 67349092220     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.009     Document Type: Article

References (37)

1. Van Laere K. In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans. Eur J Nucl Med Mol Imaging 34 (2007) 1719-1726
2. 1 cannabinoid receptors. J Nucl Med 47 (2006) 1689-1696
3. 18F]MK-9470, A positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 104 (2007) 9800-9805
4. Lynn A.B., and Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268 (1994) 1612-1623
5. 2 receptors in the brain. Neuropsychobiology 54 (2006) 231-246
6. Gustafsson K., Wang X., Severa D., Eriksson M., Kimby E., Merup M., et al. Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer 123 (2008) 1025-1033
7. 2 up-regulation in women affected by endometrial inflammation. J Cell Mol Med 12 (2008) 661-670
8. Steffens S., Veillard N.R., Arnaud C., Pelli G., Burger F., Staub C., et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434 (2005) 782-786
9. 2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95 (2005) 437-445
10. 2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101 (2007) 87-98
11. 2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27 (2007) 2396-2402
12. 2 receptor in the brain. Neurosci Lett 412 (2007) 114-117
13. Ramirez B.G. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25 (2005) 1904-1913
14. 2, regulates bone mass. Proc Natl Acad Sci USA 103 (2006) 696-701
15. Zheng D., Bode A.M., Zhao Q., Cho Y., Zhu F., and Ma W. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 68 (2008) 3992-3998
16. 2-selective ligands as immunosuppressive agents. Clin Immunol 122 (2007) 259-270
17. 2 receptor imaging. Bioconjug Chem 19 (2008) 988-992
18. 2) receptor. J Nucl Med Biol 35 (2008) 793-800
19. 2 receptor inverse agonists. J Med Chem 49 (2006) 2022-2027
20. 2 cannabinoid receptors. Bioorg Med Chem 11 (2003) 251-263
21. Larsen P., Ulin J., Dahlstrom K., and Jensen M. Synthesis of [C-11]iodomethane by iodination of [C-11]methane. Appl Radiat Isotopes 48 (1997) 153-157
22. 18F]FECT. Nucl Med Biol 35 (2008) 75-82
23. 99mTc-N-N′-bis-(mercaptoacetamido) ethylenediamine. Int J Nucl Med Biol 9 (1982) 79-82
24. 68Ga]-EDTMP. Nucl Med Biol 34 (2007) 391-397
25. Chitneni S.K., Serdons K., Evens N., Fonge H., Celen S., Deroose C.M., et al. Efficient purification and metabolite analysis of radiotracers using high-performance liquid chromatography and on-line solid-phase extraction. J Chromatogr A 1189 (2008) 323-331
26. Bradford M.M. Rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal. Biochem 72 (1976) 248-254
27. 1 cannabinoid receptor inverse agonists/antagonists. J Med Chem 49 (2006) 872-882
28. Cheng Y.C., and Prusoff W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
29. Ireland R.E., and Walba D.M. Demethylation of methyl aryl ethers: 4-ethoxy-3-hydroxybenzaldehyde. Org Synth 56 (1977) 44
30. http://146.107.217.178/lab/alogps/start.html
31. http://www.daylight.com/meetings/emug00/Ertl/tpsa.html
32. 2 receptor inverse agonists. Chem Biol Drug Des 68 (2006) 334-340
33. 2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. J Med Chem 49 (2006) 70-79
34. 2-selective agonists. Curr Med Chem 15 (2008) 1428-1443
35. 2 receptor. J Pharmacol Exp Ther 296 (2001) 420-425
36. Van de Waterbeemd H., Camenisch G., Folkers G., Chretien J.R., and Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 6 (1998) 151-165
37. Dischino D.D., Welch M.J., Kilbourn M.R., and Raichle M.E. Relationship between lipophilicity and brain extraction of C-11 labelled radiopharmaceuticals. J Nucl Med 24 (1983) 1030-1038